47 Infos zu Philippe Wiesel

14 Aktuelle Nachrichten

Cette rentrée est marquée par de nombreux changements de direction dans les écoles de Wittelsheim (lire aussi ci-dessus).

Indeed, in the US and Europe, nearly 40% of the population have NAFLD and approximately 20% are likely to develop progressive liver disease that lead

Read about a Phase 2 trial testing GKT831, a compound that showed benefits in patients with liver fibrosis, in idiopathic pulmonary fibrosis.

Phase 2 DKD trial funded by JDRF to expand in Europe and New Zealand13 patients have completed full 48-week treatment in DKD trial; no safety signals...

4 Profile in Sozialen Netzwerken

En büyük profesyonel topluluk olan LinkedIn'de Philippe Wiesel adlı kullanıcının profilini görüntüleyin. Philippe Wiesel adlı kişinin profilinde 6 iş ilanı bulunuyor.

Sehen Sie sich das Profil von Philippe Wiesel auf LinkedIn an, dem weltweit größten beruflichen Netzwerk. 6 Jobs sind im Profil von Philippe Wiesel aufgelistet.

上领英，在全球领先职业社交平台查看Philippe Wiesel的职业档案。Philippe的职业档案列出了6 个职位。查看Philippe的完整档案，结识职场人脉和查看相似公司的 ...

View the executive profile of Philippe Wiesel M.D., Executive Vice President and Chief Medical Officer at Genkyotex, on Equilar BoardEdge to see current and ...

3 Hobbys & Interessen

Genkyotex, the leading developer of selective NOX enzyme inhibitors, has started a multinational Phase II clinical study of GKT in patients with

Philippe Wiesel, Chief Medical Officer of Genkyotex, commented: “The significant effect on the primary endpoint GGT, a marker of inflammatory ...

The Company's Chief Executive Officer, Elias Papatheodorou, will present a corporate overview, and Philippe Wiesel, M.D., Genkyotex's ...

3 Infos zur Ausbildung

WIESEL Philippe : Philippe WIESEL, né en et habite STAFFELFELDEN. Aux dernières nouvelles il était à Lycée International Des Pontonniers à STRASBOURG...

Founder of Genexion SA, Philippe Wiesel presently is Chief Medical Officer & Executive Vice President at Genkyotex SA and Chief Medical Officer & Executive...

Photo de classe Philippe WIESEL

1 Bücher zum Namen

Heme oxygenase is rapidly taking its place as the centerpiece of multiple inter acting metabolic systems. Only 25 years ago heme oxygenase and its metabolic...

1 Video- & Audioinhalte

Teile deine Videos mit Freunden, Verwandten oder der ganzen Welt

1 Meinungen & Artikel

Flickriver - view images as a 'river of photos' and more...

18 Webfunde aus dem Netz

Admin. N/A, N/A, N/A. Dr. Jeanette M. Wood-Hoyle, Chief Scientific Officer, N/A, N /A, Dr. Philippe Wiesel, Chief Medical Officer & Exec. VP, N/A, N/A, N/A ...

Philippe Wiesel, CMO of Genkyotex, commented: "This newly published study shows that NOX1/4 inhibition with GKT831 is also able to reduce ...

Founder of Genexion SA, Philippe Wiesel presently is Chief Medical Officer & Executive Vice President at Genkyotex SA and Chief Medical Officer & Executive...

The Gordon Research Conference on NOX Family NADPH Oxidases will be held in Les Diablerets, VD Switzerland. Apply today to reserve your spot.

... Dina Tiniakos, Mike Trenell, Emmanuel Tsochatzis, Theresa Tunill, Antonio Vidal-Puig, Robert Walczak, Philippe Wiesel, Philippe Wiesel, Shira Zelber-Sagi. E.

Genkyotex a pu convaincre de gros investisseurs. La firme pourra tester des molécules luttant contre le diabète

... Mike Trenell, Emmanuel Tsochatzis, Theresa Tunill, Antonio Vidal-Puig, Robert Walczak, Philippe Wiesel, Philippe Wiesel, Shira Zelber-Sagi.

Sylviane Muller 1 Fanny Monneaux 1 Nicolas Schall 1 Rasho K Rashkov 2 Boycho A Oparanov 3Philippe Wiesel 4 Jean-Marie Geiger 5 Robert Zimmer 5

... de l'étude qui porteront aussi sur la fibrose et la qualité de vie des patients »commente Philippe Wiesel, Directeur Médical de Genkyotex.

“We congratulate Professor Victor Thannickal and his colleagues for obtaining FDA approval for this important trial,” said Dr. Philippe Wiesel, ...

... tumorale dans les cancers de la tête et du cou, " déclare le Dr Philippe Wiesel, vice-président exécutif et directeur médical chez Genkyotex.

Study Published in International Journal of Cancer

GenKyoTex S.A. Starts Phase I Trial with First in Class NOX Inhibitor GKT read this article along with other careers information, tips and advice on...

Genkyotex Provides Business Update and Reports Cash Position at September 30, read this article along with other careers information, tips and advice on...

m|anage your conference with our next generation system